KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Research & Development (2016 - 2025)

Historic Research & Development for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $17.3 million.

  • Halozyme Therapeutics' Research & Development fell 653.92% to $17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.0 million, marking a year-over-year decrease of 1239.51%. This contributed to the annual value of $79.0 million for FY2024, which is 351.61% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Research & Development stood at $17.3 million for Q3 2025, which was down 653.92% from $17.5 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Research & Development registered a high of $22.6 million during Q4 2022, and its lowest value of $8.1 million during Q2 2021.
  • Its 5-year average for Research & Development is $16.2 million, with a median of $17.3 million in 2023.
  • Per our database at Business Quant, Halozyme Therapeutics' Research & Development soared by 12324.89% in 2022 and then crashed by 2256.29% in 2025.
  • Halozyme Therapeutics' Research & Development (Quarter) stood at $10.1 million in 2021, then surged by 123.25% to $22.6 million in 2022, then decreased by 5.45% to $21.3 million in 2023, then decreased by 4.19% to $20.4 million in 2024, then dropped by 15.61% to $17.3 million in 2025.
  • Its Research & Development stands at $17.3 million for Q3 2025, versus $17.5 million for Q2 2025 and $14.8 million for Q1 2025.